While several molecular markers that are used to evaluate the development and prognosis of bladder cancer have been studied, the limited value of these established markers has created the need for ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

69 In this article, we will review the current available evidence assessing this application as well as various other platforms in urothelial carcinoma. In considering the application of ctDNA testing ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Early signals from an ongoing study at The Christie Hospital in Manchester shore up the evidence for an investigational treatment for the most common form of bladder cancer (urothelial carcinoma).

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

Bladder cancer can start in different parts of the bladder. The most common type starts in the cells that line the bladder — healthcare professionals refer to this as urothelial carcinoma.

She is also the chief medical officer of the lab consultancy firm Blood Associates, LLC. Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the hollow organ in your ...

Rik Bryan, Professor in Urothelial Cancer Research and Director of the Bladder Cancer Research Centre at the University of Birmingham and first author of the study said: "Bladder cancer is a ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...